BLUE

bluebird bio, Inc. (BLUE) SWOT Analysis Analysis (2026)

Invetso Score: 2.5/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Strengths

Score: 2.8 (Weak)

Blue’s negative ROIC indicates capital is not earning its cost, leaving it structurally behind profitable peers on value creation.

The company’s long cash conversion cycle ties up working capital for longer than stronger peers, reducing flexibility and compounding funding needs.

Limited disclosed margin data in the provided metrics prevents evidence of a peer-leading cost structure, which weakens the case for durable operating strength.

Weaknesses

Score:

A current ratio below 0.5 signals materially weaker short-term liquidity than healthier peers, increasing dependence on external financing or asset sales.

The quick ratio near 0.28 shows very limited near-cash coverage of obligations, leaving Blue more exposed than peers to working-capital shocks.

Negative leverage metrics in the feed suggest balance-sheet stress rather than resilience, which is structurally inferior to peers with positive coverage and lower funding risk.

The 198-day cash conversion cycle indicates slow cash recovery versus peers, which suppresses reinvestment capacity and amplifies operating fragility.

Opportunities

Score:

If Blue shortens its cash conversion cycle, it could release working capital faster than peers and improve liquidity without relying solely on new capital.

Any improvement in capital efficiency would have an outsized effect because the current low-liquidity base leaves more room for relative gains than mature peers.

A clearer segment mix disclosure could reveal concentration benefits or cross-selling leverage, but the current data do not show a proven peer advantage.

Threats

Score:

Persistently negative ROIC threatens Blue’s competitive position because peers with positive returns can compound capital while Blue destroys value.

Weak liquidity raises the risk that suppliers, lenders, or customers demand tighter terms than stronger peers, which can further pressure margins and demand.

The long cash cycle increases exposure to inventory, receivables, and funding shocks, making Blue more vulnerable than peers during tighter credit conditions.

Absent evidence of diversified segment resilience, Blue remains more exposed than peers to demand volatility in any concentrated end market.

Overall Score

Score:

Blue’s structural positioning versus peers is weak because negative capital returns and poor liquidity outweigh any unproven operating advantages.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on bluebird bio, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →